Unleash Metformin: Reconsideration of the Contraindication in Patients with Renal Impairment

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1488-1497

  Lu, Wenya R ^a   Defilippi, Jennifer ^a,b,c   Braun, Amy ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

lactic acidosis; metformin; renal insufficiency

Indexed keywords

BIGUANIDE; BIGUANIDE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LACTIC ACID; LOW DENSITY LIPOPROTEIN; METFORMIN; PHENFORMIN; SULFONYLUREA;

ANAEROBIC METABOLISM; BODY MASS; CARDIOVASCULAR RISK; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE OXIDATION; HUMAN; INCIDENCE; KIDNEY FAILURE; LACTIC ACIDOSIS; META ANALYSIS (TOPIC); MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

LACTIC ACIDOSIS; METFORMIN; RENAL INSUFFICIENCY;

ACIDOSIS, LACTIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; META-ANALYSIS AS TOPIC; METFORMIN; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84889038435     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013505428     Document Type: Review

References (42)

1. Inzucchi SE,Bergenstal RM,Buse JB,et al.Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care. 2012;35:1364-1379.
2. Bailey CJ,Path MRG,Turner RC.Metformin.N Engl J Med. 1996;334:574-579.
3. New York, NY: Bristol-Myers Squibb Company; 2009:.
4. Wu MS,Johnston P,Sheu WH,et al.Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients.Diabetes Care. 1990;13:1-8.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet. 1998;352:854-865.
6. Nathan DM,Buse JB,Davidson MB,et al.Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care. 2009;32:193-203.
7. Holman RR,Paul SK,Bethel MA,Matthews DR,Neil HA.10-Year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008;359:1577-1589.
8. Kooy A,de Jager J,Lehert P,et al.Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.Arch Intern Med. 2009;169:616-625.
9. Masoudi FA,Inzucchi SE,Wang Y,Havranek EP,Foody JM,Krumholz HM.Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.Circulation. 2005;111:583-590.
10. Eurich DT,McAlister FA,Blackburn DF,et al.Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.BMJ. 2007;335:497.
11. GunnersonKJ. Lactic acidosis. Medscape Reference2011. http://emedicine.medscape.com/article/167027-overview. Accessed September 17, 2012.
12. Chan NN,Brain HP,Feher MD.Metformin-associated lactic acidosis: a rare or very rare clinical entity?.Diabetes Med. 1999;16:273-281.
13. Schafer G.Biguanides: a review of history, pharmacodynamics and therapy.Diabetes Metab. 1983;9:148-163.
14. Tahrani AA,Varughese GI,Scarpello JH,Hanna FWF.Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?.BMJ. 2007;335:508-512.
15. Oates NS,Shah RR,Idle JR,Smith RL.Influence of oxidation polymorphism on phenformin kinetics and dynamics.Clin Pharmacol Ther. 1983;34:827-834.
16. Brown JB,Pedula K,Barzilay J,Herson MK,Latare P.Lactic acidosis rates in type 2 diabetes.Diabetes Care. 1998;21:1659-1663.
17. Stang M,Wysowski DK,Butler-Jones D.Incidence of lactic acidosis in metformin users.Diabetes Care. 1999;22:925-927.
18. Bodmer M,Jick SS,Krahenbuhl S,Meier C,Meier CR.Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.Diabetes Care. 2008 2086;31:.
19. Emslie-Smith AM,Boyle DI,Evans JM,Sullivan F,Morris AD.Contraindications to metformin therapy in patients with type 2 diabetes: a population-based study of adherence to prescribing guidelines.Diabet Med. 2001;18:483-488.
20. Nyirenda MJ,Sandeep T,Grant I,Price G,McKnight JA.Severe acidosis in patients taking metformin and survival despite high APACHE score.Diabet Med. 2006;23:432-435.
21. Van Berlo-van de Laar IRF,Vermeij CG,Doorenbos CJ.Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements.J Clin Pharm Ther. 2011;36:376-382.
22. Lalau JD,Race JM.Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations.Drug Saf. 1999;20:377-384.
23. Holstein I,Nahrwold D,Hinze S,Egberts EH.Contraindications to metformin therapy are largely disregarded.Diabet Med. 1999;16:692-696.
24. Stades AM,Heikens JT,Erkelens DW,Holleman F,Hoekstra JB.Metformin and lactic acidosis: cause or coincidence? A review of case reports.J Intern Med. 2004;255:179-187.
25. Shaw JS,Wilmot RL,Kilpatrick ES.Establishing pragmatic estimated GFR thresholds to guide metformin prescribing.Diabet Med. 2007;24:1160-1163.
26. Canadian Diabetes Association. 2008Clinical practice guidelines for the prevention and management of diabetes in Canada. http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf. Accessed January 3, 2013.
27. London, UK: Royal College of Physicians of London; 2009:.
28. Handelsman Y,Mechanick JI,Blonde L,et al.American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan.Endocr Pract. 2011;17:1-53.
29. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis. 2002;39:S1-S246.
30. Oxford University Center for Evidence-Based Medicine. Levels of evidence, March2009. http://www.cebm.net/?O=1025. Accessed October 15, 2012.
31. Rachmani R,Slavachevski I,Levi Z,Zadok B,Kedar Y,Ravid M.Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications.Eur J Intern Med. 2002;13:428-433.
32. Salpeter SR,Greyber E,Pasternak GA,Salpeter EE.Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.Arch Intern Med. 2003;163:2594-2602.
33. Pongwecharak J,Tengmeesri N,Malanusorn N,Malanusorn N,Panthong M,Pawangkapin N.Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome.Pharm World Sci. 2009;31:481-486.
34. Roussel R,Travert F,Pasquet B,et al.Metformin use and mortality among patients with diabetes and athrothrombosis.Arch Intern Med. 2010;170:1892-1899.
35. Ekström N,Schiöler L,Svensson AM,et al.Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register.BMJ Open. 2012;2:e001076.
36. Hloch O,Charvat J,Masopust J,Havlin J.Lactic acidosis in medical ICU: the role of diabetes mellitus and metformin.Neuro Endocrinol Lett. 2012;33:792-795.
37. Dvetzis V,Passadakis P,Panagoutsos S,et al.Metofrmin-related lactic acidosis in patients with acute kidney injury.Int Urol Nephrol. 2011;43:1243-1248.
38. Chu CK,Chang YT,Lee BJ,Hu SY,Hu WH,Yang DY.Metformin-associated lactic acidosis and acute renal failure in a type 2 diabetic patient.J Chin Med Assoc. 2003;66:505-508.
39. Shenoy C.Metformin-associated lactic acidosis precipitated by acute renal failure.Am J Med Sci. 2006;331:55-57.
40. Sambol NC,Chiang J,Lin ET,et al.Kidney function and age are both predictors of pharmacokinetics of metformin.J Clin Pharmacol. 1995;35:1094-1102.
41. Nye HJ,Herrington WG.Metformin: the safest hypoglycaemic agent in chronic kidney disease?.Nephron Clin Pract. 2011;118:c380-c383.
42. Lipska KJ,Bailey CJ,Inzucchi SE.Use of metformin in the setting of mild-to-moderate renal insufficiency.Diabetes Care. 2011;34:1431-1437.